Alimera Announces Multiple Presentations Highlighting ILUVIEN® and YUTIQ® Data at Retina Society Annual Congress
October 11 2023 - 8:00AM
Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global
pharmaceutical company whose mission is to be invaluable to
patients, physicians and partners concerned with retinal health and
maintaining better vision longer, announces that clinical data for
ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg and
YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg will
be featured in five presentations during the Retina Society’s 56th
Annual Scientific Meeting being held in New York City from October
11-14, 2023.
Presentations:Pouya Dayani, MD
“CALM: 24-Month Efficacy and Safety Outcomes From a Phase 4
Registry Study for Patients with Chronic Non-Infectious Posterior
Segment Uveitis Treated with a 0.18 mg Fluocinolone Acetonide
Intravitreal Insert” (Wednesday October 11, 4:17 p.m.)
Mathew MacCumber, MD, PhD “Fluocinolone
Acetonide (FAc) 0.19mg Implant Improves Vision and Treatment Burden
in Patients with Diabetic Macular Edema: The PALADIN Study” (Friday
October 13, 2:30 p.m.)
Seenu Hariprasad, MD “0.19 mg Fluocinolone
Acetonide (FAc) Implant Leads to Superior Visual-, Anatomical-, and
Treatment Burden-Related Outcomes in Eyes with Better Baseline
Visual Acuity (≥20/40)” (Friday October 13, 2:34 p.m.)
Fernando Arevalo, MD “Long-Term Outcomes in
Eyes Requiring IOP Lowering Surgery After Treatment with the 0.19
Fluocinolone Acetonide Implant for DME: The PALADIN Study” (Friday
October 13, 2:40 p.m.)
Christopher Riemann, MD “Long-Term Outcomes of
Eyes Requiring IOP Lowering Treatment (IOPT) Post Administration of
the 0.19mg Fluocinolone Acetonide (FAc) Implant for Diabetic
Macular Edema (DME)” (Friday October 13, 2:43 p.m.)
About ILUVIEN and
YUTIQwww.ILUVIEN.com www.YUTIQ.com
Both ILUVIEN and YUTIQ are sustained release intravitreal
implants injected into the back of the eye. Both utilize CONTINUOUS
MICRODOSING™ technology, which is designed to release sub-microgram
levels of fluocinolone acetonide, a corticosteroid, for up to 36
months, to reduce the recurrence of disease. ILUVIEN enables
patients to maintain vision longer with fewer injections and is
used to treat diabetic macular edema (DME) in patients who have
been previously treated with a course of corticosteroids and did
not have a clinically significant rise in intraocular pressure.
YUTIQ maintains vision longer by reducing the recurrence of
inflammation and is used for the treatment of chronic
non-infectious uveitis affecting the posterior segment of the
eye.
About Diabetic Macular Edema (DME)DME, the
primary cause of vision loss associated with diabetic retinopathy,
is a disease affecting the macula, the part of the retina
responsible for central vision. When the blood vessel leakage
associated with diabetic retinopathy results in swelling of the
macula, the condition is called DME. The onset of DME is painless
and may go unreported by the patient until it manifests with the
blurring of central vision or acute vision loss. The severity of
this blurring may range from mild to profound loss of vision. The
Wisconsin Epidemiologic Study of Diabetic Retinopathy found that
over a 10-year period approximately 19% of people with diabetes
included in the study were diagnosed with DME.
About Non-Infectious Uveitis Affecting the Posterior
Segment (NIU-PS)It is a diverse group of non-infectious
uveitic inflammatory conditions that can affect the posterior
segment of the eye. NIU-PS can affect people of all ages, producing
swelling and destroying eye tissues, which can lead to severe
vision loss and blindness and is a leading cause of working age
blindness in many countries. Patients with NIU-PS are typically
treated with systemic steroids, which are effective, but over time
frequently lead to serious side effects, ranging from acne, weight
gain, sleep and mood disorders to hypertension and osteoporosis
that can limit effective dosing. Patients then often progress to
steroid-sparing therapy with systemic immune suppressants or
biologics, which may also have severe side effects, including an
increased risk of cancer and infection.
About Alimera Sciences,
Inc.www.alimerasciences.comAlimera Sciences is a global
pharmaceutical company whose mission is to be invaluable to
patients, physicians and partners concerned with retinal health and
maintaining better vision longer. For more information, please
visit www.alimerasciences.com.
For press inquiries:Jules Abrahamfor Alimera
Sciences 917-885-7378julesa@coreir.com |
For investor inquiries:Scott Gordonfor Alimera
Sciencesscottg@coreir.com |
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Apr 2024 to May 2024
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From May 2023 to May 2024